BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 1, 2017--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Amar Sawhney, Ph.D., President and Chief Executive
Officer, will present at two upcoming investor conferences in June:
-
Jefferies 2017 Global Healthcare Conference
Presentation:
Friday, June 9, 2017 at 9:30 a.m. Eastern Time
The Grand Hyatt
New York Hotel, New York, NY
-
JMP Securities 2017 Life Sciences Conference
Panel
Discussion: “Innovations in Ophthalmology”
Tuesday, June 20, 2017
at 4:00 p.m. Eastern Time
The St. Regis New York Hotel, New York,
NY
A live audio webcast of the presentation at the Jefferies Healthcare
Conference can be accessed through the Investors section of the
Company's website at investors.ocutx.com. A replay of the webcast will
be available on the Company's website for two weeks following the live
presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. The FDA has accepted the
Company’s NDA resubmission for DEXTENZA for the treatment of ocular pain
following ophthalmic surgery and has established a PDUFA target action
date of July 19, 2017. If approved, the Company intends to submit a
supplement to its NDA for ocular inflammation. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. Ocular Therapeutix is also evaluating injectable drug
delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005160/en/
Source: Ocular Therapeutix, Inc.
Media
Medical Dynamics
Sandra Correa, 646-599-8637
Business
& Media Group Director
scorrea@rxmedyn.com
or
Investors
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular
Therapeutix
Scott Corning
Vice President of Marketing &
Commercial Operations
scorning@ocutx.com
